Moss, 15 May 2018
Gentian Diagnostics AS announces its results for the first quarter of 2018. The highlights include:
- Record level for total operating revenue of MNOK 11.2 for the quarter
- 100% growth in sales revenue compared to 1Q17
- 24 % growth in sales revenue compared to 4Q17
- Strong sales for both Cystatin C and fCal
- New Proof-of-Concept announced post end of quarter
Please find the report enclosed. The report will also be made available on www.gentian.no.
For further information, please contact:
Bård Sundrehagen
CEO, Gentian Diagnostics
E-mail: bard.sundrehagen@gentian.no
Cell Phone: +47 924 14 117
Njaal Kind
CFO, Gentian Diagnostics
E-mail: njaal.kind@gentian.no
Cell Phone. +47 919 06 525